The price of Veru Inc (NASDAQ:VERU) shares last traded on Wall Street fell -2.21% to $0.98.
Based on available information, 2 analysts follow Veru Inc (NASDAQ:VERU). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $2.00, we find $4.50. Given the previous closing price of $1.00, this indicates a potential upside of 350.0 percent. VERU stock price is now 9.22% away from the 50-day moving average and -31.42% away from the 200-day moving average. The market capitalization of the company currently stands at $88.15M.
Among analysts, 0 rate the stock a hold while 2 rate it a buy. Brokers who have rated the stock have averaged $4.50 as their price target over the next twelve months.
With the price target maintained at $1, Jefferies recently Upgraded its rating from Underperform to Hold for Veru Inc (NASDAQ: VERU).
A total of 22.93% of the company’s stock is owned by insiders.
A candlestick chart of Veru Inc (NASDAQ: VERU) showed a price of $0.9750 on Wednesday morning. During the past 12 months, Veru Inc has had a low of $0.66 and a high of $6.57. As of last week, the company has a debt-to-equity ratio of 0.71, a current ratio of 1.25, and a quick ratio of 1.02. The fifty day moving average price for VERU is $0.8946 and a two-hundred day moving average price translates $1.4240 for the stock.
The latest earnings results from Veru Inc (NASDAQ: VERU) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.07, beating analysts’ expectations of -$0.2 by 0.27. This compares to -$0.28 EPS in the same period last year. The net profit margin was -820.83% and return on equity was -178.36% for VERU. The company reported revenue of $3.34 million for the quarter, compared to $9.6 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -65.21 percent. For the current quarter, analysts expect VERU to generate $3.95M in revenue.
Veru Inc(VERU) Company Profile
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for metastatic breast cancer and for viral acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor agonist for the second line treatment of metastatic breast cancer; Enobosarm + abemaciclib, a combination versus estrogen blocking agent as secondary treatement of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
